Malignant neoplasm of overlapping sites of left bronchus and lung
ICD-10 C34.82 is a billable code used to indicate a diagnosis of malignant neoplasm of overlapping sites of left bronchus and lung.
C34.82 refers to a malignant neoplasm located at the overlapping sites of the left bronchus and lung. This condition is characterized by the uncontrolled growth of abnormal cells in the lung tissue and bronchial structures, which can lead to significant morbidity and mortality. Lung cancer is often associated with risk factors such as smoking, exposure to secondhand smoke, and environmental pollutants. The diagnosis typically involves imaging studies, such as CT scans, and histopathological examination of biopsy specimens. Staging of lung cancer is crucial for determining the prognosis and treatment options, with the TNM (Tumor, Node, Metastasis) system being the most widely used. Molecular markers, including EGFR mutations and ALK rearrangements, play a vital role in guiding targeted therapies. Treatment algorithms may include surgery, chemotherapy, radiation therapy, and immunotherapy, depending on the stage and specific characteristics of the tumor.
Detailed pathology reports, imaging studies, and treatment plans.
Initial diagnosis, staging workup, and treatment planning.
Ensure all relevant molecular testing results are documented.
Pulmonary function tests, imaging, and clinical assessments.
Management of lung cancer symptoms and complications.
Document any co-existing pulmonary conditions that may affect treatment.
Used in patients with lung cancer presenting with pleural effusion.
Document indication for procedure and findings.
Pulmonology should ensure accurate coding based on imaging findings.
Overlapping sites indicate that the tumor affects multiple anatomical structures, which can complicate staging and treatment decisions. Accurate coding is essential for appropriate management and reimbursement.
